C2i Genomics and Ichilov Join Forces to Bring Cancer Detection and Monitoring Platform to Israel

C2i Genomics, a cancer intelligence company, today announced its strategic collaboration with the Tel Aviv Sourasky Medical Center (Ichilov), Israel’s leading multidisciplinary healthcare institution. Together, the organizations will provide precision oncology clinical testing using C2inform, C2i Genomics’ whole genome minimal residual disease (MRD) test to improve cancer detection and monitoring nationwide.

C2i Genomics’ C2inform MRD test uses whole genome sequencing (WGS) to identify cancer-related mutations by employing AI-driven pattern recognition to detect traces of cancer in patient blood samples at earlier stages compared to currently available technologies. Using a unique SaaS-based approach, C2i Genomics’ cloud-based platform enables global-scale cancer tumor burden and cancer evolution monitoring, leveraging labs and sequencing networks worldwide to create cutting-edge clinical assessments and to support personalized treatment recommendations.

Through the partnership, C2i Genomics’ and its whole-genome-based assay will be integrated into a nationwide healthcare system for the first time. With Ichilov Hospital Labs serving as the reference lab for cancer hospitals across Israel, C2inform tests will become accessible to the entire population of Israel, accounting for nearly 10 million people. Through this collaboration, sequencing with WGS of circulating tumor DNA (ctDNA) and matched tumors of cancer patients will be performed by Ichilov’s Pathology Institute. Afterward, sequencing raw data will be uploaded to C2 Genomics’ cloud platform for processing and clinical interpretation. Ichilov Hospital will commercialize and offer the service to its patients while simultaneously enabling other hospitals and pharma companies in Israel to have access to the service.

“We pride ourselves on our world-class cancer research and are constantly working to offer the most effective cancer monitoring solutions not only within Israel,” said Prof. Dov Hershkovitz, Director of the Pathology Institute at Ichilov Hospital. “With C2i Genomics, we’ll ensure we stay at the cutting edge of oncological innovation to continue to provide our patients with the best possible diagnostic services.”

“We see MRD testing as a truly transformative approach in oncology and envision a day in which all cancer patients will be tested routinely for MRD, either for decisions regarding postoperative (adjuvant) treatment or for routine follow-up, possibly even replacing conventional blood tests and imaging. The Oncology Division at TLVMC has been at the forefront of precision oncology for over a decade and is a very early adaptor of novel precision medicine tools and techniques for the benefit of our patients. The collaboration with C2i Genomics will provide us a unique opportunity to be world leaders in a field that is definitely one of the most important and innovative in modern oncology,” said Prof. Ido Wolf, Director of the Oncology division at Ichilov Hospital.

“With Ichilov as our strategic partner, we’re bringing C2i’s vision of precision oncology to life,” said Boris Oklander, CTO and co-founder of C2i Genomics. “The deployment of our breakthrough technology within the hospital ecosystem marks a milestone on our journey towards a comprehensive and accessible one-stop-shop platform for precision oncology, empowering healthcare providers to drive better patient outcomes.”

In addition to assisting in developing informed treatment decisions at the individual patient level, the C2inform assay will allow for a deeper understanding of cancer biology and treatment response in diverse patient populations, contributing to future advancements in cancer care across the country. Beyond Israel, this development has significant implications for future global clinical treatment decisions and drug development, as demonstrated by C2i’s successful partnerships with global pharma companies such as AstraZeneca and genomic testing partners such as Karkinos Healthcare in India, OncoDNA across the EU, and NovogeneAIT Genomics in South East Asia.

”Ichilov is an ideal partner for C2i Genomics as we work to make our whole-genome-based cancer treatment management services available to patients globally,“ said Ezra Sofer, CEO and co-founder of C2i Genomics. ”With the hospitals’ unparalleled research resources and lab expertise, we look forward to playing an integral role in Israel’s approach to cancer treatment and further expanding our platform utilization across the globe"

About C2i Genomics:
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 3-4mL blood) and offers ultra-sensitive whole-genome sequencing cancer detection and monitoring. With headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. C2i was named to the 2021 CB Insights Digital 150 list and awarded the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award by Frost & Sullivan. For more information, please visit www.c2i-genomics.com.

Contact Information

Emma McDermott

PR for C2i Genomics

VSC for C2i Genomics

Contact via E-mail